Actively Recruiting
Hematological Anomalies in Children With Rasopathy
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-06-04
300
Participants Needed
14
Research Sites
468 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years. In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients \<3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.
CONDITIONS
Official Title
Hematological Anomalies in Children With Rasopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age less than 16 years
- Newly diagnosed with genetically confirmed rasopathy such as Noonan syndrome, type 1 neurofibromatosis, Noonan syndrome with multiple lentigines, CBL syndrome, Costello syndrome, cardiofaciocutaneous syndrome, or Legius syndrome
- Germline mutation in genes including PTPN11, SOS1, NRAS, RAF1, BRAF, SHOC2, MEK1, MEK2, CBL, NF1, SPRED1, KRAS, HRAS, SHOC2, LZTR1, SOS2, RIT1, RASA2, RRAS, PPP1CB, or new genes discovered during recruitment
- No history of hematological malignancy
- Written informed consent from parents
- Health insurance coverage
You will not qualify if you...
- History of malignant hematological pathology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
CHU Angers
Angers, France
Actively Recruiting
2
CHU Caen
Caen, France
Actively Recruiting
3
CHU Lille
Lille, France
Actively Recruiting
4
CHU Lyon
Lyon, France
Actively Recruiting
5
CHU Marseille - Hôpital de la Timone
Marseille, France
Actively Recruiting
6
CHU Montpellier
Montpellier, France
Actively Recruiting
7
CHU Nantes
Nantes, France
Actively Recruiting
8
Hôpital Necker APHP
Paris, France
Actively Recruiting
9
Hôpital Robert Debré APHP
Paris, France
Actively Recruiting
10
Hôpital Robert Debré APHP
Paris, France
Actively Recruiting
11
Hôpital Trousseau APHP
Paris, France
Actively Recruiting
12
CHU Rennes
Rennes, France
Actively Recruiting
13
CHU Strasbourg
Strasbourg, France
Actively Recruiting
14
CHU Toulouse
Toulouse, France
Actively Recruiting
Research Team
M
Marion STRULLU, MD
CONTACT
J
Jérôme Lambert, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here